Abstract
The first outbreak of influenza A virus (IAV), which has been circulating for many decades, has resulted in serious morbidity and mortality. The IAV epidemic has caused serious damage to human life and the economy. Following an IAV infection, lymphatic cells immediately enter the lungs to clear the virus and eliminate damaged cells to maintain normal physiological mechanisms. In this study, we used alpha-lipoic acid (ALA), which has versatile antioxidant functions, as a target to treat and evaluate host antiviral effects and immune mechanisms. We observed that pre-treatment with ALA improved the survival rate and pathological state in a mouse model. A reduction in the inflammatory cytokine tumor necrosis factor-alpha was observed following in vivo experiments. It also increased the release of antiviral cytokines into the lungs by T lymphocytes. ALA pre-treatment effectively prevented acute pneumonia by modulating immune composition and contributing to virus clearance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
